Fig. 2.

Effects of aspirin exposure on RUNX1 function in humans. a, In peripheral blood RNA, RUNX1 P1, P2, and the P2/P1 ratio is displayed at baseline and after 4 weeks of 325 mg/day aspirin exposure in healthy volunteers (n = 45). Data are mean ± standard error of the mean (SEM, y-axis, scaled 0.75–1.25). Panels b and c, in purified platelet RNA (B) and platelet protein (C) from healthy volunteers exposed to 325 mg/day aspirin, MYL9 expression before and after aspirin exposure is displayed. Data are SEM (y-axis, scaled 0.75–1.25). * = p-values < 0.05 for unpaired parametric two-tailed t-tests compared to DMSO at for each time point. Panel d, Using a previously described (Voora et al., 2013) composite metric of nine platelet function measures termed the Platelet Function Score, MYL9 protein expression (x-axis) is plotted versus the platelet function score (y-axis) before and after aspirin exposure in healthy volunteers. P-value represents ANOVA p-value comparing mixed-effects models with vs. without MYL9 protein expression. Shaded area represents 95% confidence interval around regression line.